常规MASS-FIX检测中单克隆轻链的N-糖基化是MGUS进展的危险因素
研究利用Olmsted MGUS筛查队列的残余血清,对414例已知MGUS患者行MASS-FIX检测,25例(6%)发现糖基化轻链。中位随访22.2年时,有和无糖基化轻链者20年进展为恶性浆细胞病的比率分别为67%(95%CI 29%, 84%)和13%(95%CI 9%, 18%),进展风险独立于Mayo MGUS风险评分。
要点
- 414例MGUS患者中25例(6%)经MASS-FIX检出糖基化轻链。
- 有糖基化轻链者20年进展为恶性浆细胞病比率为67%,无者为13%。
- 糖基化轻链是进展为AL、骨髓瘤及其他浆细胞病的强危险因素。
核心结论
- 单克隆轻链糖基化是进展为AL、骨髓瘤及其他浆细胞病的强危险因素,该发现可能有助于早期诊断并可能降低发病率与死亡率。
研究设计与样本
- 研究使用Olmsted单克隆丙种球蛋白病意义未明(MGUS)筛查队列的残余血清样本。
- 414例已知MGUS患者接受MASS-FIX检测,其中25例(6%)发现糖基化轻链。
主要发现
- 存活患者中位随访22.2年,有糖基化轻链者20年进展为恶性浆细胞病的比率为67%(95%CI 29%, 84%),无糖基化轻链者为13%(95%CI 9%, 18%)。
- 进展风险独立于Mayo MGUS风险评分。
- 有糖基化轻链者20年进展为AL的比率为21%(95%CI 0.0%, 38%),无糖基化轻链者为3%(95%CI 0.6%, 5.5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our group previously demonstrated that M-protein light chain (LC) glycosylation can be detected on routine MASS-FIX testing. Glycosylation is increased in patients with immunoglobulin LC amyloidosis (AL) and rarely changes over the course of a patient's lifetime. To determine the rates of progression to AL and other plasma cell disorders (PCDs), we used residual serum samples from the Olmsted monoclonal gammopathy of undetermined significance (MGUS) screening cohort. Four-hundred and fourteen patients with known MGUS were tested by MASS-FIX, and 25 (6%) were found to have glycosylated LCs. With a median follow-up of surviving patients of 22.2 years, the 20-year progression rates to a malignant PCD were 67% (95% CI 29%, 84%) and 13% (95% CI 9%, 18%) for patients with and without glycosylated LCs, respectively. The risk of progression was independent of Mayo MGUS risk score. The respective rates of progression to AL at 20 years were 21% (95% CI 0.0%, 38%) and 3% (95% CI 0.6%, 5.5%). In summary, monoclonal LC glycosylation is a potent risk factor for progression to AL, myeloma, and other PCDs, an observation which could lead to earlier diagnoses and potentially reduced morbidity and mortality.
引用
- Dispenzieri A, Larson DR, Rajkumar SV, et al. N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. Leukemia. 2020. PMID: 32594098. doi:10.1038/s41375-020-0940-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。